Sarepta Therapeutics
SRPT
Performance
About Sarepta Therapeutics
Sarepta Therapeutics is a global biotechnology company focused on precision genetic medicines to treat rare neuromuscular and central nervous system diseases. The company is advancing gene therapy and RNA-based approaches with an emphasis on Duchenne muscular dystrophy and related rare disorders, and is building manufacturing capacity to speed patient access. Headquartered with global operations, Sarepta collaborates across scientists, patients, and partners to bring transformative therapies to underserved populations.
Recent News
Federal Circuit’s Holding on Patent Eligibility for Engineered Host Cells Dovetails With PERA
Aurora Sets Out to Capitalize on FDA’s New Framework for Bespoke Drug Therapies
Rampart Closes Down Less Than 2 Years After Launch
Sarepta Saga Has 'Gone on Too Long' As Competitors Catch Up
Sarepta’s DMD Gene Therapy Staves Off Disease Three Years After Treatment
Arrowhead Enters Obesity Chat by Doubling Tirzepatide’s Weight Loss in Combo Study
After Mortality-Marred Year, Sarepta Looks Ahead to Catalyst-Rich 2026
Sarepta Touts Three-Year Duchenne Gene Therapy Data After Patient Deaths
Recent Deals
No recent deals for this company.
